(VKTX) Viking Therapeutics - Overview
Stock: VK2809, VK5211, VK0612, VK2735, VK0214
EPS (Earnings per Share)
Revenue
| Risk 5d forecast | |
|---|---|
| Volatility | 87.1% |
| Relative Tail Risk | -19.2% |
| Reward TTM | |
|---|---|
| Sharpe Ratio | 0.27 |
| Alpha | -36.26 |
| Character TTM | |
|---|---|
| Beta | 1.477 |
| Beta Downside | 1.034 |
| Drawdowns 3y | |
|---|---|
| Max DD | 78.86% |
| CAGR/Max DD | 0.50 |
Description: VKTX Viking Therapeutics January 11, 2026
Viking Therapeutics (NASDAQ: VKTX) is a clinical-stage biotech based in San Diego that targets metabolic and endocrine diseases. Its lead asset, VK2809, is an oral, thyroid-hormone-receptor-beta (TRβ) selective agonist currently in a Phase IIb trial for biopsy-confirmed non-alcoholic steatohepatitis (NASH) and broader NAFLD. Additional programs include VK5211 (a selective androgen receptor modulator for post-hip-fracture recovery), VK0612 (a TRβ agonist poised for Phase IIb in type-2 diabetes), VK2735 (a dual GLP-1/GLP-2 agonist in Phase I SAD/MAD), and VK0214 (TRβ-selective for X-linked adrenoleukodystrophy). The company was founded in 2012.
Key external drivers: the global NASH market is projected to exceed $15 billion by 2030, creating a sizable addressable pool for VK2809; Viking reported $115 million of cash and marketable securities at the end of 2023, giving it a runway into 2025 under current burn rates; and the broader biotech sector continues to benefit from strong venture financing and a favorable regulatory environment for metabolic therapies, though execution risk remains high.
For a deeper, data-driven look at VKTX’s valuation and risk profile, you might find ValueRay’s analyst notes worth a quick review.
Piotroski VR‑10 (Strict, 0-10) 0.0
| Net Income: error (cannot be calculated; needs Net Income TTM and Revenue TTM) |
| FCF/TA: -0.30 > 0.02 and ΔFCF/TA -22.46 > 1.0 |
| NWC/Revenue: error (cannot be calculated; needs Current Assets/Liabilities and Revenue current+prev) |
| CFO/TA -0.30 > 3% & CFO -224.6m > Net Income -237.4m |
| Net Debt/EBITDA: error (EBITDA <= 0) |
| Current Ratio: 28.34 > 1.5 & < 3 |
| Outstanding Shares: last quarter (112.3m) vs 12m ago 1.27% < -2% |
| Gross Margin: error (current vs previous; cannot be calculated due to missing/invalid data or negative margin) |
| Asset Turnover: 0.0% > 50% (prev 0.05%; Δ -0.05% > 0%) |
| Interest Coverage Ratio: -3436 > 6 (EBITDA TTM -274.4m / Interest Expense TTM 80.0k) |
Altman Z'' -15.00
| A: 0.96 (Total Current Assets 738.7m - Total Current Liabilities 26.1m) / Total Assets 739.4m |
| B: -0.93 (Retained Earnings -689.9m / Total Assets 739.4m) |
| C: -0.33 (EBIT TTM -274.8m / Avg Total Assets 838.7m) |
| D: -26.13 (Book Value of Equity -689.5m / Total Liabilities 26.4m) |
| Altman-Z'' Score: -26.36 = D |
What is the price of VKTX shares?
Over the past week, the price has changed by -4.95%, over one month by -10.14%, over three months by -24.70% and over the past year by -5.73%.
Is VKTX a buy, sell or hold?
- StrongBuy: 10
- Buy: 7
- Hold: 2
- Sell: 0
- StrongSell: 0
What are the forecasts/targets for the VKTX price?
| Issuer | Target | Up/Down from current |
|---|---|---|
| Wallstreet Target Price | 93.4 | 228.4% |
| Analysts Target Price | 93.4 | 228.4% |
| ValueRay Target Price | 32.7 | 14.8% |
VKTX Fundamental Data Overview February 04, 2026
P/EG = -0.03
Revenue TTM = 0.0 USD
EBIT TTM = -274.8m USD
EBITDA TTM = -274.4m USD
Long Term Debt = 755.0k USD (from capitalLeaseObligations, last quarter)
Short Term Debt = 437.0k USD (from shortTermDebt, last quarter)
Debt = 755.0k USD (from shortLongTermDebtTotal, last quarter)
Net Debt = -99.6m USD (from netDebt column, last quarter)
Enterprise Value = 2.67b USD (3.38b + Debt 755.0k - CCE 714.6m)
Interest Coverage Ratio = -3436 (Ebit TTM -274.8m / Interest Expense TTM 80.0k)
EV/FCF = -11.88x (Enterprise Value 2.67b / FCF TTM -224.6m)
FCF Yield = -8.42% (FCF TTM -224.6m / Enterprise Value 2.67b)
FCF Margin = unknown (Revenue TTM is 0 or missing)
Net Margin = unknown
Gross Margin = unknown ((Revenue TTM 0.0 - Cost of Revenue TTM 336.0k) / Revenue TTM)
Tobins Q-Ratio = 3.61 (Enterprise Value 2.67b / Total Assets 739.4m)
Interest Expense / Debt = 1.06% (Interest Expense 8000 / Debt 755.0k)
Taxrate = 21.0% (US default 21%)
NOPAT = -217.1m (EBIT -274.8m * (1 - 21.00%)) [loss with tax shield]
Current Ratio = 28.34 (Total Current Assets 738.7m / Total Current Liabilities 26.1m)
Debt / Equity = 0.00 (Debt 755.0k / totalStockholderEquity, last quarter 713.0m)
Debt / EBITDA = 0.36 (negative EBITDA) (Net Debt -99.6m / EBITDA -274.4m)
Debt / FCF = 0.44 (negative FCF - burning cash) (Net Debt -99.6m / FCF TTM -224.6m)
Total Stockholder Equity = 808.9m (last 4 quarters mean from totalStockholderEquity)
RoA = -28.31% (Net Income -237.4m / Total Assets 739.4m)
RoE = -29.35% (Net Income TTM -237.4m / Total Stockholder Equity 808.9m)
RoCE = -33.94% (EBIT -274.8m / Capital Employed (Equity 808.9m + L.T.Debt 755.0k))
RoIC = -26.84% (negative operating profit) (NOPAT -217.1m / Invested Capital 808.9m)
WACC = 11.36% (E(3.38b)/V(3.38b) * Re(11.36%) + D(755.0k)/V(3.38b) * Rd(1.06%) * (1-Tc(0.21)))
Discount Rate = 11.36% (= CAPM, Blume Beta Adj.)
Shares Correlation 3-Years: 100.0 | Cagr: 5.92%
Fair Price DCF = unknown (Cash Flow -224.6m)
EPS Correlation: -38.32 | EPS CAGR: 8.04% | SUE: 4.0 | # QB: 1
Revenue Correlation: 2.80 | Revenue CAGR: -0.01% | SUE: 0.0 | # QB: 0
EPS next Quarter (2026-03-31): EPS=-0.94 | Chg30d=+0.000 | Revisions Net=+1 | Analysts=7
EPS next Year (2026-12-31): EPS=-3.72 | Chg30d=+0.001 | Revisions Net=-1 | Growth EPS=-42.3% | Growth Revenue=+0.0%